Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Authors:
- D. StrumbergDSD. Strumberg
- A. AwadaAAA. Awada
- H. HirteHHH. Hirte
- J.W. ClarkJCJ.W. Clark
- S. SeeberSSS. Seeber
- P. PiccartPPP. Piccart
- E. HofstraEHE. Hofstra
- D. VoliotisDVD. Voliotis
- O. ChristensenOCO. Christensen
- A. BruecknerABA. Brueckner
- B. SchwartzBSB. Schwartz
- 1 March 2006
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 42 (4) , 548-556
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and AngiogenesisMolecular and Cellular Biology, 2004
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Final results of a phase I study of the Raf-1 kinase inhibitor bay 43-9006 in patients with advanced refractory solid tumoursEuropean Journal of Cancer, 2002
- ZD1839: targeting the epidermal growth factor receptor in cancer therapyExpert Opinion on Investigational Drugs, 2002
- Ras family genes: An interesting link between cell cycle and cancerJournal of Cellular Physiology, 2002
- Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras ActivationJournal of Biological Chemistry, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine KinasesBiochemical and Biophysical Research Communications, 1999